Delcath Systems Inc Dossier
Qualitative Analysis
Business overview
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary lead product is the HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), a drug/device combination approved by the FDA in August 2023 as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases. Delcath also commercializes the device-only configuration of this system under the trade name CHEMOSAT Hepatic Delivery System for Melphalan in Europe. These systems are designed to administer high-dose chemotherapy directly to the liver while surgically isolating the organ's circulatory system to filter the blood and limit systemic exposure and toxic side effects.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the network of REMS-certified hospital sites and training interventional oncology teams to perform percutaneous hepatic perfusion (PHP) procedures using the HEPZATO KIT.
Expected impact: Establishes a robust, repeatable commercial engine and drives procedural volume growth across key geographic regions.
Advancing the clinical pipeline of HEPZATO, including evaluating its efficacy in patients with liver-dominant metastatic colorectal cancer (mCRC) and liver-dominant metastatic breast cancer (mBC) through Phase 2 clinical trials.
Expected impact: Enables potential regulatory submission for label expansion into colorectal liver metastases, which represents a vastly larger commercial opportunity than uveal melanoma.
Developing an upgraded, next-generation hepatic delivery system designed to improve filtration efficiency, simplify procedural setup, and increase operator consistency.
Expected impact: Reduces procedural burden on hospital staff and expands accessibility of the platform beyond top-tier academic medical centers.
Executing a board-authorized $25 million share buyback program to repurchase outstanding common stock and enhance shareholder value.
Expected impact: Reduces share count and demonstrates capital allocation discipline and confidence in the company's long-term cash flow generation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborative research to develop advanced filtration cartridges for potential use in Delcath's percutaneous hepatic perfusion (PHP) system, aiming to optimize the removal of chemotherapeutic agents from blood.
Terms: Joint research and development terms (specific financial figures not disclosed).